Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-863 dose-finding placebo-controlled study in pulmonary hypertension associated with interstitial lung disease
MOH_2026-09-22_017045Phase 3Not yet recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of NS-863 in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD) (3 arms), sponsored by NS Pharma, Inc. Primary endpoints: Change in pulmonary vascular blood flow/hemodynamics, Cardiac function and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
NS-863
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)interstitial lung disease (ILD)
Beyond the preview
Go deeper on MOH_2026-09-22_017045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-22_017045.